28/06/2007 13:00:00

Quantum Genomics Corp Partners with Inserm and CNRS in Hypertension Drug Development

Quantum Genomics Corp. (QGC), a global biotech company developing

new drugs for metabolic and cardiovascular diseases, announced

partnership agreements with Inserm, the French national institute for

health and medical research and the CNRS, France´s national center for

scientific research, and University Paris Descartes. The agreement

brings together some of the best scientific skills in the field of

cardiovascular diseases from two leading life science research

organizations and a premier university along with biotechnology

business experience from QGC, to successfully co-develop innovative

drugs.

The agreement covers a lead molecule derived from discoveries by

teams led respectively by Dr Catherine Llorens-Cortes, director of

Inserm Unit 691, based in the College de France and by Prof. Bernard

P. Roques at Inserm Unit 640, itself based in the University of Paris

Descartes.

The purpose of the agreement is to co-develop innovative drugs for

hypertension and related cardiovascular diseases. Under the terms of

the contract, QGC acquires rights to exploit three patents and

associated know-how. Inserm and CNRS will work on the physiopathology,

chemistry and the understanding of the compound´s mechanism of action

whereas QGC will handle preclinical and clinical development and

regulatory aspects.

The first lead molecule to be developed will be QGC001, a new

chemical entity. This compound acts according to a new biological

mechanism with a huge potential to facilitate control of blood

pressure in patients who are resistant to currently available

anti-hypertension drugs. QGC expects to start the first clinical trial

in humans in 2008.

"We are delighted to be partnering with Inserm and CNRS, two of

the world´s leading healthcare research organizations," said Lionel

Segard, Chairman and CEO of QGC. "This project lets QGC demonstrate

its ability to develop new drugs in compliance with international

regulatory guidelines. It also significantly reinforces QGC´s

potential in R&D in the field of cardiovascular diseases."

"This partnership with QGC gives us an excellent opportunity to

accelerate the pre-clinical and clinical development of a project

based on work carried out in our labs in close cooperation with

Bernard Roques´ team," said Catherine Llorens Cortes, director of

Inserm Unit 691.

Cardiovascular diseases are one of the main causes of death in

humans. Hypertension in particular is one of the major determining

factors in premature death. The risk of myocardial infarction, stroke,

kidney failure, heart failure or other complications doubles with

every 20/10mmHg rise in blood pressure. At least 30% of people have

hypertension. Hundreds of millions of people worldwide suffer from

hypertension complications despite medical advice on food and health

habits and the existence of several treatments. The market for

hypertensive drugs is expected to double between 2005 and 2010.

About Quantum Genomics Corp.

QGC is a biotechnology company seeking to develop new therapies in

areas where an unmet medical need exists. QGC focus is on

metabolism-related diseases and cardiovascular pathologies. It will

co-develop some products with academic teams and will set up strategic

alliances and commercial partnerships to cover all areas of research

in life sciences.

The company is headquartered in Jersey City, New Jersey, USA. It

has a European office in France under the leadership of Lionel Segard.

For more information go to www.Quantum-Genomics.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
20 Sep
 
Godt vi får bremset udviklingen i landet - Jeg håber også DK bliver det sidste land med selvkørende ..
19
23 Sep
NETS-TEMP
Det her er en klassisk case, hvor kapitalfondene på for kort tid, har fået lov til at realisere en s..
17
21 Sep
GEN
12% af dette er Genmabs - de har trinvis stigende royalty gående fra 12% til 20%. Og hvis man tolker..
16
25 Sep
 
Professor Jesper Rangvid fra CBS kom fredag med en stor kritik af private danske aktionærer. Han har..
14
15:40
OMXC20CAP
Er der ikke en admin eller sådan noget der kan slette baronen? Magen til evnesvag person der er yder..
11
21 Sep
BAVA
  Betydningen af de reviderede data er nok begrænset omend de peger i den rigtige retning.   Når jeg..
11
23 Sep
ZEAL
Åhhh nej begynder du nu igen. Kan du ikke også lige smide et postulat omkring noget blodbad mandag s..
9
21 Sep
GEN
Stigning 25% op i forhold til sidste måned. Mon ikke vi skal over de 1150 idag. 1300 here we come.
9
15:34
OMXC20CAP
Mener du "over bord"!? 
8
14:18
 
Mogens Lykketoft har fået det meste ud af sin totale mangel af praktiske evner. Tænk at kunne leve h..
8

Majedie Asset Management Ltd : Form 8.3 - PREMIER FARNELL PLC

26/09/2016 15:47:44
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% O..

OZ Management LP : Form 8.3 - London Stock Exchange Group Plc

26/09/2016 13:59:23
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Novae Group plc: Director/PDMR Shareholding

23/09/2016 15:40:16
1 Details of the person discharging managerial responsibilities/ person closely associated ("PCA") ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease
2
Bionor Pharma ASA : Primary insider notification - Gunnar Flåten
3
Wärtsilä to participate in research programme aimed at creating an ecosystem for autonomous marine transport
4
Bionor Pharma ASA : Primary inside Notification - Maja A. Sommerfelt
5
FAIVELEY TRANSPORT TO SUPPLY HVAC SYSTEMS FOR THE NEW GENERATION OF S-BAHN TRAINS IN BERLIN, GERMANY

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2016   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
26 September 2016 21:43:25
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20160921.1 - EUROWEB6 - 2016-09-26 22:43:25 - 2016-09-26 21:43:25 - 1000 - Website: OKAY